BNCT for recurrent intracranial meningeal tumours ? case reports

Stenstam, Britta; Pellettieri, Luigi; Sorteberg, Wilhelm; Rezaei, Arash; Sköld, K.

doi:10.1111/j.1600-0404.2006.00776.x

Cited by 15 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Two of the three anaplastic meningiomas showed a complete response, and all six patients analyzed showing radiographic improvement (39). Stenstam et al described two patients treated with BNCT using BPAfructose (900 mg/kg body weight) for recurrent meningeal tumors following surgery, radiation, and salvage surgery and concluded that BNCT is a potentially effective modality for malignant intracranial meningeal tumors (40).…”

Section: Meningiomamentioning

confidence: 99%

Boron Neutron Capture Therapy: A Review of Clinical Applications

et al. 2021

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is an emerging treatment modality aimed at improving the therapeutic ratio for traditionally difficult to treat tumors. BNCT utilizes boronated agents to preferentially deliver boron-10 to tumors, which, after undergoing irradiation with neutrons, yields litihium-7 and an alpha particle. The alpha particle has a short range, therefore preferentially affecting tumor tissues while sparing more distal normal tissues. To date, BNCT has been studied clinically in a variety of disease sites, including glioblastoma multiforme, meningioma, head and neck cancers, lung cancers, breast cancers, hepatocellular carcinoma, sarcomas, cutaneous malignancies, extramammary Paget’s disease, recurrent cancers, pediatric cancers, and metastatic disease. We aim to provide an up-to-date and comprehensive review of the studies of each of these disease sites, as well as a review on the challenges facing adoption of BNCT.

show abstract

Section: Meningiomamentioning

confidence: 99%

Boron Neutron Capture Therapy: A Review of Clinical Applications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…It has already been used in patients with various types of brain malignances, including glioblastomas (7)(8)(9)(10)(11)(12), anaplastic meningiomas (13), cerebral melanoma metastases (14), or tumors recurrences in inoperable anatomic locations (15,16). In this context, a few Phase I (7,8,10,11) and Phase II studies (8,10) have consistently demonstrated no severe effects of BNCT-related toxicity, and some preliminary evidence of therapeutic effectiveness (7,9,12) has been presented. From a technical point of view, BNCT is based on the intratumoral delivery of a stable boron isotope ( 10 B nucleus) featuring high cross-section for thermal neutrons capture.…”

Section: Introductionmentioning

confidence: 99%

L-DOPA Preloading Increases the Uptake of Borophenylalanine in C6 Glioma Rat Model: A New Strategy to Improve BNCT Efficacy

Capuani

Gili

Bozzali

et al. 2008

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Purpose: Boron neutron capture therapy (BNCT) is a radiotherapeutic modality based on 10 B(n,a) 7 Li reaction, for the treatment of malignant gliomas. One of the main limitations for BNCT effectiveness is the insufficient intake of 10 B nuclei in the tumor cells. This work was aimed at investigating the use of L-DOPA as a putative enhancer for 10 B-drug 4-dihydroxy-borylphenylalanine (BPA) uptake in the C6-glioma model. The investigation was first performed in vitro and then extended to the animal model. Methods and Materials: BPA accumulation in C6-glioma cells was assessed using radiowave dielectric spectroscopy, with and without L-DOPA preloading. Two L-DOPA incubation times (2 and 4 hours) were investigated, and the corresponding effects on BPA accumulation were quantified. C6-glioma cells were also implanted in the brain of 32 rats, and tumor growth was monitored by magnetic resonance imaging. Rats were assigned to two experimental branches: (1) BPA administration; (2) BPA administration after pretreatment with L-DOPA. All animals were sacrificed, and assessments of BPA concentrations in tumor tissue, normal brain, and blood samples were performed using high-performance liquid chromatography. Results: L-DOPA preloading induced a massive increase of BPA concentration in C6-glioma cells only after a 4-hour incubation. In the animal model, L-DOPA pretreatment produced a significantly higher accumulation of BPA in tumor tissue but not in normal brain and blood samples. Conclusions: This study suggests the potential use of L-DOPA as enhancer for BPA accumulation in malignant gliomas eligible for BNCT. L-DOPA preloading effect is discussed in terms of membrane transport mechanisms. Ó

show abstract

“…Clinical studies of second-generation boron delivery agents are listed in Table 1 [ 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 ]. Current research originates from many institutions around the world.…”

Section: Application Of Second-generation Boron Delivery Agentsmentioning

confidence: 99%

Boron Neutron Capture Therapy: Clinical Application and Research Progress

Cheng

Liu³

2022

Current Oncology

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a binary modality that is used to treat a variety of malignancies, using neutrons to irradiate boron-10 (10B) nuclei that have entered tumor cells to produce highly linear energy transfer (LET) alpha particles and recoil 7Li nuclei (10B [n, α] 7Li). Therefore, the most important part in BNCT is to selectively deliver a large number of 10B to tumor cells and only a small amount to normal tissue. So far, BNCT has been used in more than 2000 cases worldwide, and the efficacy of BNCT in the treatment of head and neck cancer, malignant meningioma, melanoma and hepatocellular carcinoma has been confirmed. We collected and collated clinical studies of second-generation boron delivery agents. The combination of different drugs, the mode of administration, and the combination of multiple treatments have an important impact on patient survival. We summarized the critical issues that must be addressed, with the hope that the next generation of boron delivery agents will overcome these challenges.

show abstract

BNCT for recurrent intracranial meningeal tumours ? case reports

Cited by 15 publications

References 15 publications

Boron Neutron Capture Therapy: A Review of Clinical Applications

Boron Neutron Capture Therapy: A Review of Clinical Applications

L-DOPA Preloading Increases the Uptake of Borophenylalanine in C6 Glioma Rat Model: A New Strategy to Improve BNCT Efficacy

Boron Neutron Capture Therapy: Clinical Application and Research Progress

Contact Info

Product

Resources

About